Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

from hydroxyurea therapy. Fully HLA matched siblings will be used as donors for hematopoietic stem cells to reduce the risk of morbidity and mortality in this cohort of patients.

cell transplantation
carbon monoxide
alemtuzumab
chest syndrome
osteonecrosis
  • 28 views
  • 28 Jan, 2021
  • 1 location
Frontline Asciminib Combination in Chronic Phase CML

pretreatment with hydroxyurea is permitted. Patients treated for <6 weeks with nilotinib 300 mg BID, imatinib 400 mg QD, or dasatinib 100 mg QD are eligible for recruitment and will be allocated to the

nilotinib
leukemia
imatinib
imatinib 400 mg
dasatinib
  • 0 views
  • 02 Feb, 2021
  • 37 locations
Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)

adulthood. HbF induction is one of the best strategies to ameliorate the characteristic symptoms of these diseases. Hydroxyurea (HU) is the only medication, approved by the US Food and Drug Administration

  • 0 views
  • 03 Feb, 2021
  • 4 locations
Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor

peripheral blood after - + cells obtained from pediatric and young adult patients with SCD. To study the effect of hydroxyurea therapy on senescence in plerixafor-mobilized CD34+ cells obtained

  • 0 views
  • 06 May, 2021
  • 1 location
Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

days and, if taking hydroxyurea, have not had a dose change in the past 90 days). Design Participants will be screened with a physical exam, medical history

  • 0 views
  • 11 Apr, 2021
  • 1 location
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

alemtuzumab
graft versus host disease
iron
chest syndrome
direct bilirubin
  • 18 views
  • 26 Jan, 2021
  • 1 location
Reduced Intensity Transplantation for Severe Sickle Cell Disease

This study is being done to test a transplant method that may have fewer side effects (or less toxic, less harmful) than conventional high dose chemotherapy conditioning-based transplants for children and young adults with Sickle Cell Disease (SCD). Patients less than or equal to 25 years old with SCD who …

alemtuzumab
chest syndrome
transcranial doppler ultrasonography
hemoglobinopathy
plerixafor
  • 0 views
  • 25 Jan, 2021
  • 1 location
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)

This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) …

fludarabine
iron
anti-thymocyte globulin
asthma
chest syndrome
  • 201 views
  • 24 Jan, 2021
  • 28 locations
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell disease (SCD). The long-term …

  • 0 views
  • 24 Feb, 2021
  • 1 location
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

This study assesses the potential of using a TGF receptor inhibitor for the treatment of anemic patients with myeloproliferetive neoplasms. TGF signaling is known to be abnormally high in patients with myeloproliferative neoplasms and it is thought that abnormal TGF signals cause many of the problems with blood cell formation …

myelodysplastic/myeloproliferative neoplasm
ruxolitinib
hydroxyurea
anemia
  • 0 views
  • 28 Jan, 2021
  • 1 location